Genmab A/S (NASDAQ:GMAB) Receives $39.17 Average Price Target from Analysts
Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one […]
Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one […]
